Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5171242 | 1.00 | CHRM2 (0.69) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL1549648 | 1.00 | CHRM2 (0.69) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL9834955 | 0.90 | CHRM1 (0.64) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL21218778 | 0.89 | CHRNA7 (0.60) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL3743481 | 0.85 | CHRM2 (0.71) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL4874804 | 0.84 | CHRM2 (0.65) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL4637799 | 0.84 | CHRM2 (0.65) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL1566368 | 0.82 | CHRM2 (0.67) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL21063805 | 0.82 | CHRM2 (0.67) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| (S)-Aceclidine SCHEMBL9146471 | 0.82 | CHRM2 (1.00) | CHRM2CHRM1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305676-B1 | Synthesis of solifenacin monosuccinate | ASTELLAS PHARMA INC (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-7829715-B2 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-11-09 | — | — | US | disclosed |
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | ASTELLAS PHARMA INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1757604-A1 | PROCESS FOR PRODUCING SOLIFENACIN OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1487834-A1 | AZA-BICYCLIC N-BIARYLAMIDES WITH AFFINITY FOR THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR | Bayer Aktiengesellschaft (DE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078431-A1 | AZA-BICYCLIC N-BIARYLAMIDES WITH AFFINITY FOR THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR | BAYER HEALTHCARE AG (DE) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185329-A1 | Method for producing solifenacin or salts thereof | SUCNR1, GLS, CACNA1S | CHRM2 92/4885CHRM1 75/4885CYP2D6 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.